Status: Not yet recruiting
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Vivani Medical, IncUpdated: Jun 30, 2026
Eligibility criteria
BMI between 27 and 40 kg/m2 (inclusive) [+3]
Type 1 or Type 2 Diabetesa [+2]